- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.12 | 0.09 | 37.29 |
| EPS, GAAP | 0.09 | 0.09 | 0.09 |
| Consensus Estimate | 0.20 | 0.21 | -3.07 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 0.44 | 0.00 | -2.69 |
| EPS, GAAP | 0.29 | 0.00 | -36.30 |
| Consensus Estimate | 0.97 | 0.87 | 10.93 |
| QGEN | Industry Average | |
| P/E (TTM) | 0.00 | NA |
| P/E (Forward) | 15.80 | NA |
| PEG Ratio | 1.59 | 2.17 |
| Price/Sales | 3.48 | 4.18 |
| Beta | 0.27 | 0.62 |
| 3/29/2012 | Roche Should Resist More Genetic Engineering (WSJ.com) |
![[sm061210things]](http://s.wsj.net/public/resources/images/PF-AC562_sm0612_C_20120514113337.jpg)
![[sm0612wedding4]](http://s.wsj.net/public/resources/images/PF-AC579_sm0612_C_20120515172853.jpg)
![[sm0612strat]](http://s.wsj.net/public/resources/images/PF-AC580_sm0612_C_20120515180019.jpg)
![[sm0612roi]](http://s.wsj.net/public/resources/images/PF-AC573_sm0612_C_20120515125902.jpg)